thalidomide has been researched along with Duodenal Diseases in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Duodenal Diseases: Pathological conditions in the DUODENUM region of the small intestine (INTESTINE, SMALL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with lenalidomide, as the final therapeutic option, resolved the intractable melena and improved both the intestinal lesions and myeloma." | 5.39 | Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis. ( Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S, 2013) |
| "Postoperative pathology confirmed Crohn's disease." | 1.48 | [The 465th case: intestinal obstruction, gastrointestinal hemorrhage and duodenal fistula]. ( Guo, F; Li, JN; Li, XQ; Ma, ZQ; Qian, JM; Wang, YN; Xue, HD; Yang, AM; Zhou, WX, 2018) |
| "Treatment with lenalidomide, as the final therapeutic option, resolved the intractable melena and improved both the intestinal lesions and myeloma." | 1.39 | Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis. ( Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, YN | 1 |
| Li, XQ | 1 |
| Guo, F | 1 |
| Yang, AM | 1 |
| Qian, JM | 1 |
| Li, JN | 1 |
| Xue, HD | 1 |
| Zhou, WX | 1 |
| Ma, ZQ | 1 |
| Nagano, S | 1 |
| Mori, M | 1 |
| Kato, A | 1 |
| Ono, Y | 1 |
| Aoki, K | 1 |
| Arima, H | 1 |
| Takiuchi, Y | 1 |
| Tabata, S | 1 |
| Yanagita, S | 1 |
| Matsushita, A | 1 |
| Ishikawa, T | 1 |
| Imai, H | 1 |
| Takahashi, T | 1 |
2 other studies available for thalidomide and Duodenal Diseases
| Article | Year |
|---|---|
[The 465th case: intestinal obstruction, gastrointestinal hemorrhage and duodenal fistula].
Topics: Anastomosis, Surgical; Colon; Crohn Disease; Cutaneous Fistula; Digestive System Surgical Procedures | 2018 |
Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis.
Topics: Aged; Amyloid; Amyloidosis; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; | 2013 |